HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.